GlassScriptPhysician profile
Thomas D Perkins
NPI 1508859042
$2,505.43
in general payments reported to CMS, 2019-2025
33 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $430 · 2021: $602 · 2022: $455 · 2023: $213 · 2024: $199 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $342.01 | 2019-2022 | |
| Abbvie INC. | $251.17 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.38 | 2020-2025 | Trintellix |
| Glaxosmithkline, LLC. | $162.81 | 2019-2023 | Arexvy, Shingrix |
| Jazz Pharmaceuticals INC. | $128.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.50 | 2020-2022 | |
| Abbott Laboratories | $119.11 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $109.88 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $102.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $90.75 | 2020-2023 | |
| Pfizer INC. | $83.17 | 2020-2025 | |
| Allergan, INC. | $80.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $74.54 | 2022 | |
| Axsome Therapeutics, INC. | $62.24 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $59.21 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $59.19 | 2019-2022 | |
| Eisai INC. | $54.01 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.52 | 2020-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $41.44 | 2024 | Voquezna |
| Tris Pharma INC | $40.30 | 2023-2024 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $37.18 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.82 | 2021 | |
| Exact Sciences Corporation | $29.63 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $28.02 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.94 | 2022 | |
| Cipher Pharmaceuticals US LLC | $21.84 | 2025 | Spinosad, Natroba |
| Sunovion Pharmaceuticals INC. | $20.47 | 2022 | |
| Genentech USA, INC. | $17.73 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.07 | 2022 | |
| Adlon Therapeutics L.P. | $14.17 | 2021 | |
| Shire North American Group INC | $13.24 | 2019 | |
| Dexcom, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.